Acumen Pharmaceuticals, Inc. (ABOS) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2022 and Business Highlights
August 15, 2022 4:05 PM EDTTopline results expected in the first half of 2023 from INTERCEPT-AD, a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose Phase 1 clinical trial of ACU193 in patients with early Alzheimers disease (AD)
Key methods and assay model developed to potentially standardize the study of soluble amyloid-beta oligomers (AOs) presented in a poster at the recent Alzheimers Association International Conference (AAIC)$209.9 million in cash, cash equivalents and marketable securities as of June 30, 2022, which is expected to provide cash... More
